HUP9904434A2 - Pirazolo[4,3-d]pirimidinon-, kinazolinon-, purinon- és pirido[3,2-d]pirimidinon-származékok alkalmazása nitrát-indukált tolerancia kezelésére szolgáló gyógyszerkészítmények előállítására - Google Patents

Pirazolo[4,3-d]pirimidinon-, kinazolinon-, purinon- és pirido[3,2-d]pirimidinon-származékok alkalmazása nitrát-indukált tolerancia kezelésére szolgáló gyógyszerkészítmények előállítására

Info

Publication number
HUP9904434A2
HUP9904434A2 HU9904434A HUP9904434A HUP9904434A2 HU P9904434 A2 HUP9904434 A2 HU P9904434A2 HU 9904434 A HU9904434 A HU 9904434A HU P9904434 A HUP9904434 A HU P9904434A HU P9904434 A2 HUP9904434 A2 HU P9904434A2
Authority
HU
Hungary
Prior art keywords
pyrimidinones
nitrate
induced
pyrido
induced tolerance
Prior art date
Application number
HU9904434A
Other languages
English (en)
Inventor
Peter Ellis
Original Assignee
Pfizer Research And Development Company N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company N.V./S.A. filed Critical Pfizer Research And Development Company N.V./S.A.
Publication of HU9904434D0 publication Critical patent/HU9904434D0/hu
Publication of HUP9904434A2 publication Critical patent/HUP9904434A2/hu
Publication of HUP9904434A3 publication Critical patent/HUP9904434A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Atalálmány tárgyát képezi a nitrátindűkált tőlerancia kezelésérealkalmas gyógyászati készítmények előállítása, amelyek valamilyengyógyászatilag elfőgadható hőrdőzó-, hígító- vagy vivőanyaggalkőmbinálva, hatóanyagként pirazőlő[4,3-d]pirimidinőn-, kinazőlinőn-,pűrinőn- és piridő[3,2-d]pirimidinőn-származékőkat vagy ezekgyógyászatilag elfőgadható sóit, elővegyületeit, pőlimőrf váltőzatait,hidrátjait, szőlvátjait, aktív metabőlitjait vagy sztereőizőmerjeit anitrátindűkált tőlerancia kezeléshez szükséges mennyiségben alkalmazvatartalmaznak. Szintén a találmány tárgyát képezi emlősöknitrátindűkált tőleranciájának megelőzése, amelynek sőrán az arrarászőrűló emlősnek egy cGMP PDE inhibitőr nitrátindűkált tőleranciamegelőzéséhez szükséges hatásős mennyiségét adják be. ŕ
HU9904434A 1998-11-30 1999-11-29 Use of pyrazolo[4,3-d]pyrimidinones, quinazolinones, purinones pyrido[3,2-d]pyrimidinones for the preparation of pharmaceutical compositions treating nitrate-induced tolerance HUP9904434A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11033598P 1998-11-30 1998-11-30

Publications (3)

Publication Number Publication Date
HU9904434D0 HU9904434D0 (en) 2000-01-28
HUP9904434A2 true HUP9904434A2 (hu) 2000-08-28
HUP9904434A3 HUP9904434A3 (en) 2003-06-30

Family

ID=22332455

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904434A HUP9904434A3 (en) 1998-11-30 1999-11-29 Use of pyrazolo[4,3-d]pyrimidinones, quinazolinones, purinones pyrido[3,2-d]pyrimidinones for the preparation of pharmaceutical compositions treating nitrate-induced tolerance

Country Status (10)

Country Link
US (1) US6225315B1 (hu)
EP (1) EP1022026A3 (hu)
JP (1) JP2000159672A (hu)
KR (1) KR100363714B1 (hu)
AU (2) AU767452B2 (hu)
CA (1) CA2290766C (hu)
HU (1) HUP9904434A3 (hu)
IL (1) IL133078A (hu)
NZ (1) NZ515501A (hu)
ZA (1) ZA997371B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US20010053780A1 (en) * 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
US7034027B2 (en) 2000-08-02 2006-04-25 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
GB0106661D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
AU2002317377A1 (en) * 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
DE10238722A1 (de) 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238724A1 (de) * 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE602004007840T2 (de) * 2003-03-18 2008-04-10 The Jordanian Pharmaceutical Manufacturing Co. Ltd. Pyrazolopyrimidinon und ihre Verwendung als PDE-Inhibitoren
DE10320785A1 (de) * 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Arylmethyl-substituierte Pyrazolopyrimidine
US8044060B2 (en) * 2003-05-09 2011-10-25 Boehringer Ingelheim International Gmbh 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
DE102004001873A1 (de) * 2004-01-14 2005-09-29 Bayer Healthcare Ag Cyanopyrimidinone
CN1966506A (zh) * 2005-11-17 2007-05-23 上海特化医药科技有限公司 吡唑并嘧啶酮衍生物及其制备方法和用途
JP2010505811A (ja) * 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
CN101429166B (zh) * 2007-11-07 2013-08-21 上海特化医药科技有限公司 喹唑啉酮衍生物及其制备方法和用途
JP5498392B2 (ja) * 2007-11-30 2014-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
PE20110383A1 (es) 2008-09-08 2011-07-15 Boehringer Ingelheim Int Pirazolopirimidinonas como inhibidores de la fosfodiesterasa 9a (pde9a)
KR20120003868A (ko) 2009-03-31 2012-01-11 베링거 인겔하임 인터내셔날 게엠베하 １―헤테로사이클릴―１,５―디하이드로―피라졸로［３,４―ｄ］피리미딘―４―온 유도체 및 ｐｄｅ９ａ 조절인자로서의 이의 용도
AR077859A1 (es) * 2009-08-12 2011-09-28 Boehringer Ingelheim Int Compuestos para el tratamiento de trastornos del snc
BR112013003097B1 (pt) 2010-08-12 2021-03-16 Boehringer Ingelheim International Gmbh 6-cicloalquil-pirazolopirimidinonas e composição farmacêutica
CN102020645B (zh) * 2010-09-30 2012-12-12 中山大学 吡唑并嘧啶酮衍生物及其可药用盐、其制备方法和应用
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
KR20210096626A (ko) * 2018-11-28 2021-08-05 토파두르 파마 아게 가용성 구아닐레이트 사이클라제 활성제 및 포스포디에스테라제 억제제의 신규한 이중 작용 방식 및 이의 용도
CN112079835B (zh) * 2019-06-12 2022-03-01 广州华真医药科技有限公司 一种5型磷酸二酯酶抑制剂的钾盐晶型b及其制备方法和应用
CA3156783A1 (en) * 2019-11-09 2021-05-14 Yun Jin Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof
KR20210056827A (ko) * 2019-11-11 2021-05-20 일동제약(주) 신규한 벤젠설폰아미드 유도체 및 그의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9119704D0 (en) 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
US5614530A (en) 1995-03-10 1997-03-25 Sterling Winthrop Inc. Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
US5656629A (en) 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
US5488055A (en) 1995-03-10 1996-01-30 Sanofi Winthrop Inc. Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
EP0813534A4 (en) 1995-03-10 1998-06-10 Sanofi Winthrop Inc 6-ARYL PYRAZOLO 3,4-D] PYRIMIDIN-4-ONES, COMPOSITIONS AND METHODS OF USE THEREOF
CA2288910C (en) 1997-04-25 2003-06-24 Pfizer Inc. Pyrazolopyrimidinones for sexual dysfunction
GB9823101D0 (en) * 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds

Also Published As

Publication number Publication date
KR20000035774A (ko) 2000-06-26
EP1022026A3 (en) 2002-04-10
AU2004200573A1 (en) 2004-03-11
HU9904434D0 (en) 2000-01-28
CA2290766A1 (en) 2000-05-30
KR100363714B1 (ko) 2002-12-06
CA2290766C (en) 2003-02-04
ZA997371B (en) 2001-05-29
EP1022026A2 (en) 2000-07-26
AU2004200573B2 (en) 2007-02-08
JP2000159672A (ja) 2000-06-13
AU6178899A (en) 2000-06-01
HUP9904434A3 (en) 2003-06-30
US6225315B1 (en) 2001-05-01
IL133078A (en) 2006-10-31
IL133078A0 (en) 2001-03-19
NZ515501A (en) 2003-08-29
AU767452B2 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
HUP9904434A2 (hu) Pirazolo[4,3-d]pirimidinon-, kinazolinon-, purinon- és pirido[3,2-d]pirimidinon-származékok alkalmazása nitrát-indukált tolerancia kezelésére szolgáló gyógyszerkészítmények előállítására
IL163781A (en) Purine derivatives as kinase inhibitors
GEP20063784B (en) Optical Resolution of (1-Benzyl-4- Methylpiperidin-3-Yl) -Methylamine Enantiomers and Use Thereof for Preparation of Pyrrolo 2,3-Pyrimidine Derivatives as Protein Kinases Inhibitors
GEP20053479B (en) Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
ES2166270A1 (es) Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
CA2421120A1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
BG103195A (en) Substituted indazole derivatives and their application as inhibitors of phosphodiesterase (pde) type iv and of the production of a tumournecrotic factor (tnf)
HUP0004708A2 (hu) 1,2,4-Triazolo[4,3-b]pirido[3,2-d]piridazin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
GEP20033142B (en) Pyrazolo (4,3-D) Pyrimidine Derivatives
IL122855A0 (en) 7H-pyrrolo [2,3-d] pyrimidine derivatives their preparation and pharmaceutical compositions containing them
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
MY133311A (en) Novel imidazopyridines as cyclin dependent kinase inhibitors
AU1729097A (en) Quinazoline derivatives as vegf inhibitors
WO2001019829A3 (en) Pyrazolopyrimidines as therapeutic agents
HUP9801602A2 (hu) Imidazo[1,2-a]piridin-származékok, eljárás ezek előállítására, ezeket tartalmazó gyógyászati készítmények, és alkalmazásuk
ATE297208T1 (de) Tablette mit verlängerter wirkstoffabgabe zur behandlung der parkinsonkrankheit
HU9403112D0 (en) Process for producing quinolin-4-amine-and 1h-imidazo[4,5-c]quinolin-4-amine derivatives as intermediates
GEP20053511B (en) ) β-Carboline Derivatives Useful as Inhibitors of Phosphodiesterase
IL108520A (en) 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
CA2209487A1 (en) Imidazo[4,5-c]quinoline amines
MY140398A (en) 4-AMINO-6-PHENYL-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES
AU4567193A (en) Anilide derivatives
ATE250602T1 (de) Pyrimido(6,1-a)isochinolinonderivate
HUP0104406A3 (en) Use of pde v inhibitors for the preparation of pharmaceutical compositions increasing fecundity in mammals
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.